Press Releases

August 19, 2022
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
PDF Version
August 16, 2022
IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
PDF Version
August 12, 2022
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
PDF Version
August 11, 2022
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
PDF Version
July 27, 2022
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
PDF Version